A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.

Vasc Health Risk Manag · 2014 · PMC4045264 · PMID 24920915

Europe PMC DOI

hedged sentence

0.1730

closest p · 3.5× alpha

0.1730

boldest claim

The sentences

did not reach statistical significanceP =0.173not close (p > 0.1)

Hypoglycemia The proportion of patients who reported any HE during the Ramadan fasting period was numerically lower in the vildagliptin 50 mg bid plus metformin group (6.0%) compared with the gliclazide plus metformin group (8.7%); however, the difference between treatments did not reach statistical significance ( P =0.173; one-sided test).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.